Connect with us

News

Thousands in England set to benefit from ‘repurposed’ drug to prevent breast cancer

Around 2,000 cases would be prevented if 25 per cent of eligible women in England take up the offer, according to NHS England

Published

on

Tens of thousands of women in England could benefit from a “repurposed” NHS drug that could help prevent breast cancer.

Anastrozole, which has been used for many years as a breast cancer treatment, has been licensed as a preventive option, in a move that could help prevent around 2,000 cases of breast cancer in England.

The drug, which is off-patent, has been shown in trials to reduce the incidence of the disease in post-menopausal women at increased risk of the disease by almost 50 per cent.

It was first recommended as a preventive option by the National Institute for Health and Care Excellence in 2017, however, with the treatment being unlicensed in this use, uptake has remained low.

An estimated 289,000 women could be eligible for the drug.

While not all patients will choose to take it, it is estimated that if 25 per cent do, around 2,000 cases of breast cancer in England could potentially be prevented.

NHS chief executive, Amanda Pritchard, said: “It’s fantastic that this vital risk-reducing option could now help thousands of women and their families avoid the distress of a breast cancer diagnosis.

“Allowing more women to live healthier lives, free of breast cancer is truly remarkable, and we hope that licensing anastrozole for a new use today represents the first step to ensuring this risk-reducing option can be accessed by all who could benefit from it.

“This is the first drug to be repurposed through a world-leading new programme to help us realise the full potential of existing medicines in new uses to save and improve more lives on the NHS.

“Thanks to this initiative, we hope that greater access to anastrozole could enable more women to take risk-reducing steps if they’d like to, helping them live without fear of breast cancer.”

Lesley-Ann Woodhams, 61, was offered anastrozole off-label for the prevention of breast cancer due to being at increased risk of developing the disease, and having a family history of breast cancer. She completed the full five-year course of anastrozole in January.

She said: “Taking anastrozole was an easy decision for me, as I’d watched my mum battle breast cancer and my risk was very high.

“Anastrozole reduced my risk of developing breast cancer, meaning I could live a life without constantly worrying or giving a thought to what could be if I’d developed breast cancer.

“It really was a gift, it gave my family and myself peace of mind and more importantly, a continued future to look forward to. I’m grateful for every day I took this drug – it was life-changing.”

She added: “Anastrozole has allowed me to continue living my life as I’d planned.”

Breast cancer remains the most common cancer in England, with 47,000 people being diagnosed each year.

Anastrozole is the first medicine to be repurposed through a new multi-agency national programme that looks at using existing medicines in new ways to benefit patients and the NHS.

The treatment is an aromatase inhibitor and works by cutting down the amount of the hormone oestrogen that a patient’s body makes by blocking an enzyme called “aromatase”.

Health minister, Will Quince, said: “Breast cancer is the most common cancer in the UK so I’m delighted that another effective drug to help to prevent this cruel disease has now been approved.

“We’ve already seen the positive effect Anastrozole can have in treating the disease when it has been detected in post-menopausal women and now we can use it to stop it developing at all in some women.

“This is a great example of NHS England’s innovative Medicines Repurposing Programme supporting the development of new ways for NHS patients to benefit from existing treatments.”

Baroness Delyth Morgan, chief executive at the charity Breast Cancer Now, said: “The extension of anastrozole’s licence to cover it being used as a risk-reducing treatment is a major step forward that will enable more eligible women with a significant family history of breast cancer, to reduce their chance of developing the disease.

“For the past decade, Breast Cancer Now has been tirelessly campaigning with clinicians, researchers and patients for drugs that are found to be effective and safe in new uses to reach people who could benefit, and we were thrilled when NHS England set up the Medicines Repurposing Programme.

“Anastrozole was the first drug to be supported by the programme and this paves the way for improving access to risk-reducing drugs,” she continued.

“We look forward to continuing our work with NHS England to further improve access to these drugs for everyone eligible.”

To receive the Femtech World newsletter, sign up here.

News

Menopause start-up bags US$60m in funding

Midi Health aims to expand access to insurance-covered care for women in midlife and beyond

Published

on

Midi Health Series B round investors and founders, pictured from left: GV Executive venture partner Cathy Friedman, Midi Health co-founder Kathleen Jordan, Midi Health co-founder Jill Herzig, Felicis Ventures general partner Victoria Treyger, Operator Collective founder Mallun Yen, Midi Health co-founder Sharon Meers, Midi Health co-founder and CEO Joanna Strober, Emerson Collective managing partner Fern Mandelbaum, SemperViren partner Allison Baum Gates, GV general partner Frederique Dame

The US menopause start-up Midi Health has secured US$60m in funding, bringing the company’s total funding raised to date to US$100m.

The funding round was led by Emerson Collective, with support from additional investors, including GV (Google Ventures), Memorial Hermann, SemperVirens, Felicis, Icon Ventures, Black Angel Group, Gingerbread Capital, Able Partners, G9 and Operator Collective.

They joined a syndicate of primarily female-led investors including F7, Steel Sky Ventures, Avestria, Muse Capital, 1843 Capital, Anne WojcickiSusan Wojcicki, and K50 Ventures.

Founded with a mission to close this care gap, Midi is now the fastest-growing virtual clinic focused on treating women in perimenopause and menopause.

The California start-up, which expanded to all 50 states in November, aims to help women navigating midlife hormonal changes.

The company provides patients with care plans that include hormonal and non-hormonal medications, supplements and lifestyle coaching and has partnerships with major healthcare systems, such as Memorial Hermann and benefits platforms, such as Progyny and Cleo.

The additional investment round is hoped to help Midi expand insurance coverage, hire and upskill an additional 150 clinicians, diversify service lines, amplify the conversation around women’s health and scale to care for over one million women per year by 2029.

“We started Midi with just one specific focus: helping women access world-class, expert perimenopause and menopause care, covered by insurance, and we have been at the forefront of delivering on that promise,” Joanna Strober, CEO and co-founder of Midi, explained.

“But what we have also learned is that addressing the health concerns of women in midlife is more complex than simply treating hot flashes and prescribing hormone replacement therapy.

“Midi takes a multi-symptom, holistic approach to care designed to help women live their best, most productive and fulfilling lives—whether that involves medication, lifestyle coaching, natural supplements, or other support.

“Our goal now is to expand services and scope to continue this comprehensive, personalised care far beyond menopause.”

Women spend more than a third of their lives in perimenopause or menopause, with more than one billion women globally expected to be in these life stages by 2030.

Upwards of 85 per cent of women will experience menopausal symptoms that can negatively impact their productivity and quality of life, yet 75 per cent of women who seek care for these symptoms do not receive any treatment.

The primary reason is that only about one in five OB/GYNs, and even fewer primary care physicians, receive specialised menopause education or training.

“Historically, women’s healthcare has been neglected, with perimenopause and menopause having significant unmet needs,” said Fern Mandelbaum of Emerson Collective.

“Midi is providing expert, empathetic care coupled with comprehensive insurance coverage, finally addressing this gap and ensuring that all women receive the support they need and deserve.”

To receive the Femtech World newsletter, sign up here.

Continue Reading

News

Start-up launches London Underground campaign to break down period stigma

The two-week campaign seeks to challenge societal taboos surrounding menstrual health

Published

on

The Irish women’s health start-up Riley has launched an ad campaign on the London Underground to “take the fear out of periods”.

Riley, an eco-friendly period product subscription service, aims to take action against period poverty and democratise access to period products.

The company seeks to encourage the introduction of menstrual health policies and foster a workplace where discussions around periods are normalised.

Its two-week London Underground campaign, which coincides with the opening of its first office in London, is hoped to help destigmatise periods and normalise conversations around menstrual health.

“The idea behind this campaign comes from the fact that free period care in the office is often seen as an employee perk or a ‘nice to have’, when it should actually be an essential offering in every office,” Meaghan Droney, eCommerce manager at Riley, told Femtech World.

“Our aim with this campaign is to flip those current mindsets and get people to change their attitudes towards period care in the workplace.

“With 79 per cent of menstruators feeling unsupported in relation to their periods at work, this oversight is clearly fundamentally unfair and it’s time for change.

“We’re encouraging any and all businesses to get in touch with us so we can support them in introducing menstrual policies and free period care in their workplace to empower all employees, no matter their gender, to thrive and feel valued at work.”

Research by the Chartered Institute of Personnel and Development (CIPD) shows that only 12 per cent of UK companies provide support for menstruation and menstrual health, despite 85 per cent of women experiencing stress or anxiety when managing their period at work.

Data suggests that half of the women who take absence because of their menstrual cycle feel unable to tell their manager, underscoring the deep-rooted stigma around periods.

Fiona Parfrey, co-founder of Riley, said: “Access to safe and high-quality sustainable period care products not only demonstrates a commitment to employee welfare but also fosters a culture of empathy, equality, and respect, ultimately contributing to a more engaged and empowered workforce.

“Menstrual policies and free period care are a fundamental necessity for every individual in the workplace. It’s about ensuring that employees have the resources they need to maintain their wellbeing and productivity without interruption.”

To receive the Femtech World newsletter, sign up here.

Continue Reading

News

Singapore-based fertility centre sets up grant for couples struggling to conceive

This grant aims to support eligible Singaporean couples facing financial and family planning challenges

Published

on

A Singapore-based fertility centre is to set up a grant to support couples struggling to conceive.

Virtus Fertility Centre Singapore (VFCS) announced that it would set up a grant to support aspiring parents on their IVF journey.

The initial grant is set for at $50,000 SGD and, depending on the take-up rate over the next 12 fiscal months, VFCS plans to increase the pool to benefit more couples in the subsequent years.

The grant will cover the main costs associated with IVF treatments and procedures, including embryo retrieval and transfer, laboratory services and embryo prep. It will also be applicable to fresh and frozen egg transfers.

As grant recipients, their samples will similarly be given a radio frequency identification (RFID) tag, a service VFCS provides for all its patients. It locks the patient’s identity with the respective sample. The RFID identifies gametes—eggs, sperms, or embryos—at every stage of the IVF treatment.

According to VFCS, the grant will also include access to counselling services and wellness resources.

“I’ve witnessed firsthand the emotional toll and occasional frustration that infertility can take on individuals and couples, especially for some who are still young and healthy,” said Dr Roland Chieng, medical director at VFCS.

“The common deterrent of going for fertility treatment is always associated with the cost, more so in a private care setting where their only source of funds is through Medisave.

“By alleviating their financial concerns, we hope ReadyBaby Fertility Grant empowers patients to approach their IVF journey, focusing on their clinical needs and working towards a healthy pregnancy and less on financials.

“With access to the necessary treatments and support, patients can embark on their path to parenthood with renewed confidence, knowing they have the clinical resources and guidance they need to navigate this journey,” he added.

Tim Kwan, VFCS’s managing director, said: “We believe every couple deserves the opportunity to experience the profound joy of parenthood.

“With the ReadyBaby Fertility Grant, we aim to support aspiring couples on their IVF journey and help them bring new life into the world.”

To be eligible for the grant, applicants must be married Singaporean couples diagnosed with medical infertility by a fertility specialist and first-time parents who have not tried IVF before.

To receive the Femtech World newsletter, sign up here.

Continue Reading

Trending

Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.